Oncotarget

Errata:

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

PDF  |  How to cite

Oncotarget. 2018; 9:32400-32400. https://doi.org/10.18632/oncotarget.26017

Metrics: PDF 870 views  |   ?  

Joan T. Garrett1, Anindita Chakrabarty1 and Carlos L. Arteaga1,2,3

1 Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
2 Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
3 Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Published: August 17, 2018

This article has been corrected: During production, the text of the subsections ‘INHIBITION OF P13K IS INCOMPLETE WITH SINGLE AGENTS’ and ‘CLINICAL IMPLICATIONS’ was duplicated within the article. The corrected version now has the duplicated text removed while preserving the original pagination.

Original article: Oncotarget. 2011; 2:1314-1321. DOI: https://doi.org/10.18632/oncotarget.409.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26017